Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases

Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases

Abstract Tumor heterogeneity is a primary cause of treatment failure. However, changes in drug sensitivity over time are not well mapped in cancer. Patient-derived organoids (PDOs) may predict clinical drug responses ex vivo and offer an opportunity to evaluate novel treatment strategies in a person...

Full description

Bibliographic Details
Main Authors: Kushtrim Kryeziu, Seyed H. Moosavi, Christian H. Bergsland, Marianne G. Guren, Peter W. Eide, Max Z. Totland, Kristoffer Lassen, Andreas Abildgaard, Arild Nesbakken, Anita Sveen, Ragnhild A. Lothe
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Journal of Translational Medicine
Subjects:
Rectal cancer
Liver metastasis
Patient-derived organoid
LCL161
Online Access:https://doi.org/10.1186/s12967-021-03062-3

Internet

https://doi.org/10.1186/s12967-021-03062-3

Similar Items